S-nitrosoderivative of a recombinant fragment of von Willebrand factor (S-nitroso-AR545C) inhibits thrombus formation in guinea pig carotid artery thrombosis model

Thrombosis and Haemostasis

Volumn 84, Issue 5, 2000, Pages 912-917

  Gurevitz, O ^a   Eldar, M ^a   Skutelsky, E ^a   Tamarin, I ^a   Shenkman, B ^a   Eskaraev, R ^a   Castel, D ^a   Loscalzo, J ^a   Inbal, A ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Nitric oxide; Platelet inhibitors; Von Willebrand factor

Indexed keywords

NITROSO DERIVATIVE; S NITROSO AR545C; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG SYNTHESIS; GUINEA PIG; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 0033710137     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614136     Document Type: Article

References (35)

1. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets
2. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
3. A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with cyclic flow
4. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
5. New antiplatelet agents for acute coronary syndromes
6. Effect of type IIb von Willebrand disease mutation Arg (545) Cys on platelet glycoprotein Ib binding: Studies with recombinant von Willebrand factor
7. Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model
8. Unique antiplatelet effects of a novel S-nitrosoderivative of a recombinant fragment of von Willebrand factor, AR545C: In vitro and ex vivo inhibition of platelet function
9. A scheme for the colorimetric determination of microgram amounts of thiols
10. A new method for quantitative analysis of whole blood and platelet interaction with extracellular matrix under flow conditions
11. Cone and plate(let) analyser: Monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions
12. Rat model of arterial thrombosis induced by ferric chloride
13. Synthesis by guinea pig megakariocytes of platelet glycoprotein receptors for fibrinogen and von Willebrand factor
14. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries
15. A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis
16. Vitronectin inhibits the thrombotic response to arterial injury in mice
17. Anti-thrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries
18. Antagonism of the GPIIbIIIa receptor with the nonpeptidic molecule BIBU52: Inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo
19. Effects of TAK-029, a novel GPIIbIIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys
20. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrocysteine than nitric oxide
21. Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelet
22. The antiplatelet effects of organic nitrates and related nitroso-compounds in vitro and in vivo and their relevance to cardiovascular disorders
23. Intravenous nitroglycerine infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries
24. Sodium nitroprusside, an endothelium-derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries
25. Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrosodilators
26. Nitric oxide generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
27. L-arginine inhibits balloon catheter-induced intimal hyperplasia
28. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury
29. L-arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty
30. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor in rat carotid artery intimal injury
31. FK 409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty
32. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury
33. Effects of NO donors on thrombus formation and microcirculation in cerebral vessels of the rat
34. 2 production
35. Comparison of antiplatelet effects of two nitric oxide donating agents. FR146801 and FK 409